TECX.O (TECX.O) News
Follow TECX.O (TECX.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Tectonic Therapeutic gets FDA Fast Track for TX2100 in hereditary hemorrhagic telangiectasia
FDA granted Fast Track designation for TX2100 to treat hereditary hemorrhagic telangiectasia and cleared an IND to start a Phase 1b U.S. trial in HHT patients, with Phase 1b initiation targeted by year-end 2026.
EQUITY | Sep 29, 2026, 09:20 PM UTC
M
Tectonic Therapeutic reports favorable Phase 1a results for TX2100 in HHT
The company said TX2100 was generally safe and well tolerated with no serious safety signals in single-dose cohorts, and plans open-label Phase 1b by year-end 2026 and placebo-controlled Phase 2 in early 2027.
EARNINGS | Sep 29, 2026, 12:11 PM UTC